Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATR12-351
- Development stage
- Phase 1
- Lead developer
- Azitra
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
ATR12-351 is a genetically engineered strain of *Staphylococcus epidermidis* developed as a topical therapy for Netherton syndrome and related congenital ichthyoses. The bacterium is modified to express and deliver an active subunit of the human lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein directly into the skin. LEKTI deficiency, caused by mutations in the *SPINK5* gene, underlies Netherton syndrome—a rare and severe genetic skin disorder characterized by chronic inflammation and barrier dysfunction. By restoring functional LEKTI at the site of disease through bacterial delivery, ATR12-351 aims to inhibit excessive activity of kallikrein-related peptidase 5 (KLK5), reduce inflammatory cytokines such as IL-36γ, and address the root cause of disease pathology. The drug is being developed by Azitra in collaboration with The Jackson Laboratory and has entered Phase 1b clinical trials for adult patients with Netherton syndrome[3][4][5][6][7][8].
- Other names
- Staphylococcus epidermidis SE351 expressing LEKTI
02
Targets
KLK5 (Kallikrein-related peptidase 5)KLK7KLK14 (Kallikrein-related peptidase 14)KLK6 (Kallikrein-related peptidase 6)
Beyond the preview
Go deeper on ATR12-351.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATR12-351.